Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Dec;32(6):427-430.
doi: 10.1159/000453084. Epub 2016 Nov 30.

Systemic Therapy of Cholangiocarcinoma

Ruben R Plentz  1 , Nisar P Malek  1
Affiliations
Review

Systemic Therapy of Cholangiocarcinoma

Ruben R Plentz et al. Visc Med. 2016 Dec.

Abstract

Background: Cholangiocarcinoma (CC) is the second most common primary malignant liver disease. During the last decades, various novel therapies have been introduced in the field of oncology; nevertheless, the number of treatment options for CC is still limited.

Methods: In this article, current palliative chemotherapy concepts as well as new drug therapies are outlined.

Results: Gemcitabine and cisplatin are the standard treatment of care for patients with inoperable CC. Second-line chemotherapy is not standardized yet and is dependent on the first-line compounds. Antibodies against VEGFR and EGFR showed mixed or negative results. New molecular systemic treatments are not established yet.

Conclusion: Many clinical trials are still ongoing and new therapeutic strategies, including immunotherapies, are under active investigation.

Keywords: Chemotherapy; Cholangiocarcinoma; Survival.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Treatment options for inoperable cholangiocarcinoma.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Wang Y, Li J, Xia Y, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol. 2013;31:1188–1195. - PubMed
    1. West J, Wood H, Logan RF, Quinn M, Aithal GP. Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001. Br J Cancer. 2006;94:1751–1758. - PMC - PubMed
    1. Shaib YH, Davila JA, McGlynn K, El Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol. 2004;40:472–477. - PubMed
    1. Alvaro D, Crocetti E, Ferretti S, Bragazzi MC, Capocaccia R. Descriptive epidemiology of cholangiocarcinoma in Italy. Dig Liver Dis. 2010;42:490–495. - PubMed
    1. von Hahn T, Ciesek S, Wegener G, Plentz RR, Weismüller TJ, Wedemeyer H, Manns MP, Greten TF, Malek NP. Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany. Scand J Gastroenterol. 2011;46:1092–1098. - PubMed